Artwork

Kandungan disediakan oleh medicalminute and Emergency Medical Minute. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh medicalminute and Emergency Medical Minute atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.
Player FM - Aplikasi Podcast
Pergi ke luar talian dengan aplikasi Player FM !

Episode 905: Oseltamivir (Tamiflu) for Influenza

2:37
 
Kongsi
 

Manage episode 420532994 series 1397179
Kandungan disediakan oleh medicalminute and Emergency Medical Minute. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh medicalminute and Emergency Medical Minute atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

Contributor: Aaron Lessem MD

Educational Pearls:

  • Oseltamivir (Tamiflu) is an antiviral medication used commonly to treat influenza

  • Trials show that the medication reduces the duration of illness by less than 1 day (~16 hours in one systematic review)

    • Benefit only occurs if taken within 48 hours of symptom onset

    • Must be taken for 5 days

  • A 2024 meta-analysis reviewed 15 randomized-controlled trials for the risk of hospitalization

    • No reduction in hospitalizations with oseltamivir in patients over the age of 12

    • No difference in high-risk patients over the age of 65 or those with comorbidities

      • The authors note that the confidence interval in these populations is wide, indicating a need for subsequent studies in high-risk populations

  • Oseltamivir is associated with adverse effects including nausea, vomiting, and neurologic symptoms

    • The risk of adverse effects may outweigh the benefits of a small reduction in the duration of illness

References

1. Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699

2. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(April):1-18. doi:10.1136/bmj.g2545

Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit

  continue reading

1083 episod

Artwork
iconKongsi
 
Manage episode 420532994 series 1397179
Kandungan disediakan oleh medicalminute and Emergency Medical Minute. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh medicalminute and Emergency Medical Minute atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

Contributor: Aaron Lessem MD

Educational Pearls:

  • Oseltamivir (Tamiflu) is an antiviral medication used commonly to treat influenza

  • Trials show that the medication reduces the duration of illness by less than 1 day (~16 hours in one systematic review)

    • Benefit only occurs if taken within 48 hours of symptom onset

    • Must be taken for 5 days

  • A 2024 meta-analysis reviewed 15 randomized-controlled trials for the risk of hospitalization

    • No reduction in hospitalizations with oseltamivir in patients over the age of 12

    • No difference in high-risk patients over the age of 65 or those with comorbidities

      • The authors note that the confidence interval in these populations is wide, indicating a need for subsequent studies in high-risk populations

  • Oseltamivir is associated with adverse effects including nausea, vomiting, and neurologic symptoms

    • The risk of adverse effects may outweigh the benefits of a small reduction in the duration of illness

References

1. Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699

2. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(April):1-18. doi:10.1136/bmj.g2545

Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit

  continue reading

1083 episod

Semua episod

×
 
Loading …

Selamat datang ke Player FM

Player FM mengimbas laman-laman web bagi podcast berkualiti tinggi untuk anda nikmati sekarang. Ia merupakan aplikasi podcast terbaik dan berfungsi untuk Android, iPhone, dan web. Daftar untuk melaraskan langganan merentasi peranti.

 

Panduan Rujukan Pantas

Podcast Teratas